On November 5th, Frontline Bio (688221.SH) announced that the company has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, approving the company to conduct Phase II clinical trials for the indication of maintenance therapy for its marketed product, Ecalning, in accordance with the submitted plan. Ecalning is a domestically developed Class 1.1 new drug, the world's first long-acting HIV fusion inhibitor that has been approved, with independent intellectual property rights in major global markets. Ecalning, when used in combination with other antiretroviral drugs, is effective against the main strains of HIV-1 virus as well as drug-resistant viruses. It has the characteristics of low dosing frequency, fast onset of action, high resistance barrier, high safety, and minimal side effects.